Joint drug procurement office: The 11th batch of 55 varieties of centrally-purchased drugs, with 25 reference preparations participating, accounting for approximately one third of the total sales.

On September 20th, the National Drug Centralized Procurement Office announced the 11th batch of national organized drug centralized procurement documents. According to the Drug Centralized Procurement Office, a total of 46,359 medical institutions nationwide participated in the bidding. 77% of the bids from medical institutions were specific to the brand, while 23% were based on generic names. Out of the 55 varieties included in this centralized procurement, 25 had generic drugs participating, with a bid share of approximately 30%. The person in charge of the Drug Centralized Procurement Office pointed out that the bidding ratio for this centralized procurement is similar to previous ones, with about 80% of the bids from medical institutions being the agreed procurement quantity. For varieties with 3 or fewer selected enterprises, the bidding ratio is appropriately reduced. Based on this, department and expert opinions were adopted to lower the bidding ratio by 10-20 percentage points for corticosteroid drugs, antibacterial drugs, varieties with limited indications for use, and key monitoring drugs, reducing it to 60-70%.